Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

raltegravir

- PMLiVE

Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use

An estimated 1.2 million people in the US are currently living with the virus

- PMLiVE

MHRA approves Bavarian Nordic’s chikungunya vaccine Vimkunya

Approximately 620,000 cases of the mosquito-borne viral disease were reported worldwide in 2024

- PMLiVE

MHRA urges companies to prepare for Windsor Framework for medicines

The new UK-wide arrangements for medicines will come into effect on 1 January 2025

- PMLiVE

Ipsen’s Iqirvo approved by MHRA to treat primary biliary cholangitis in adults

Approximately 25,000 people in the UK are affected by the rare liver disease

- PMLiVE

Pfizer/BioNTech’s Omicron JN.1-adapted COVID-19 vaccine approved by MHRA

The UK regulator has approved four versions of the updated vaccine for adults and children from infancy

- PMLiVE

Novo Nordisk’s semaglutide approved by MHRA to prevent cardiovascular event risk

Approximately 7.6 million people are living with heart and circulatory diseases in the UK

- PMLiVE

GSK’s ViiV shares positive head-to-head results for two-drug HIV regimen Dovato

The phase 4 trial has been comparing Dovato against Gilead’s three-drug regimen, Biktarvy

- PMLiVE

MHRA approves first generic raltegravir medicines to treat HIV in adults and children

More than 91,000 people in England were diagnosed with HIV and accessing care in 2022

- PMLiVE

Gilead shares positive phase 3 results for twice-yearly HIV PrEP drug in women

Lenacapavir demonstrated 100% efficacy in protecting more than 2,000 women against the infection

- PMLiVE

UCB’s Bimzelx granted MHRA approval to treat hidradenitis suppurativa in adults

The authorisation applies to patients who have had an inadequate response to conventional systemic HS therapy

- PMLiVE

Takeda’s Takhzyro granted MHRA approval for younger hereditary angioedema patients

The rare genetic disorder is estimated to affect one in every 50,000 people

- PMLiVE

MHRA approves TMC Pharma’s Nulibry to treat rare genetic disease MoCD type A

Molybdenum cofactor deficiency is estimated to affect one in 100,000 to 200,000 newborns worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links